

HemoShear Therapeutics Has Built a World Class Drug Discovery Organization to Advance its Rare Disease Portfolio

More than 30 Scientists Working to Discover New Medicines

HemoShear has created a robust drug discovery organization with a portfolio of research programs that are making rapid progress in identifying drug targets and potential candidates to treat rare diseases with high unmet medical need.

“Our chief scientific officer Brian Johns, PhD, came to us after a prolific career at GSK where he was the co-inventor of two marketed drugs. In three years at HemoShear Brian has built out a team of highly experienced and dedicated scientists who are making incredible strides,” says Brian Wamhoff, PhD, interim CEO. “Thanks to this team, our research pipeline is expanding beyond HST5040, our drug currently in a phase 2 clinical trial for methylmalonic and propionic acidemias, to include programs for other rare diseases.”



Brian Johns, PhD

“We started from scratch and have successfully moved multiple programs rapidly into lead optimization and initiated exploratory programs aimed at uncovering new science to replenish the pipeline as we find success or attrition along the way,” says Dr. Johns. “While we are not yet ready to disclose the diseases we are pursuing, I am extremely proud of the diligence the team has invested in identifying conditions with high unmet need, gaining insights into the drivers of these diseases and uncovering druggable targets.”

The drug discovery group integrates more than 30 scientists with a wide range of expertise across biology, pharmacology, biomedical engineering, computational sciences, and medicinal chemistry to create novel medicines. HemoShear’s

REVEAL-Tx™ platform remains a central feature, utilizing primary human cells and computational biology to build disease models to not only identify novel biological targets but also characterize drug mechanisms and candidates. The biology team has made use of traditional high throughput screens as well as cutting edge AI approaches to find high quality hits. From there the team of medicinal chemists and pharmacologists are working to optimize drug candidates for the HemoShear development organization to move rapidly into the clinic.

“HemoShear has the organizational strategy, structure and people in place for successful rare disease drug discovery,” says Robert Gould, PhD, HemoShear board chair and former president and CEO of Fulcrum Therapeutics. “I look forward to the team continuing to make progress as they execute on their plan.”

Learn More!

Click [here](#) to learn more about the HemoShear advantage in drug discovery.

